Navigation Links
Amicus Therapeutics Announces Preliminary Results of Phase 2 Study with Plicera(TM) for Gaucher Disease
Date:10/2/2009

disease is estimated to affect approximately 10,000 people in the developed world. The U.S. Food and Drug Administration's Office of Orphan Products Development has granted orphan drug designation for the active ingredient in Plicera in the United States and the European Commission has designated Plicera as an orphan medicinal product in the European Union.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs.

Amicus has a strategic collaboration with Shire Human Genetic Therapies, Inc., a wholly-owned subsidiary of Shire plc, to develop and commercialize Amicus' three lead pharmacological chaperone compounds for lysosomal storage disorders. Under the agreement, Shire received commercial rights outside of the United States. Amicus retains all U.S. rights.

Forward-Looking Statements

This press release contains and the accompanying conference call will contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to clinical development of Amicus' investigational drug product, Plicera(TM) (afegostat tartrate) the timing and reporting of final results from clinical trials evaluating Amicus' investigational drug products, and the projected cash position for the Company at the end of 2009. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "should" and "could
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Amicus Brief Filed with U.S. Supreme Court in Riegel v. Medtronic, Inc.
2. Retail Industry Leaders Association Files Amicus in California Health Care Litigation
3. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference on September 14, 2009
4. Prime Therapeutics Receives TIPPS Certification
5. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
6. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
7. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
8. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
9. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
10. Adams Respiratory Therapeutics Announces FDA Approval of Grape-Flavored Delsym(R)
11. Prime Therapeutics Announces URAC Accreditation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Wailea, Maui, HI (PRWEB) July 29, 2014 ... Four Seasons Resort Maui at Wailea. This September through ... many of them free-- tailored to couples of all ages ... great and guests can take advantage of the Resort's popular ... to $1,000 while the "twice yearly sale" is in full ...
(Date:7/29/2014)... Tucson-based company Outski has created a ... and wellness program, called 401(play)™. A 401(play)™ plan promotes ... for employees to use their earned vacation time. In ... the amount of each paycheck to be put into ... offering a 401(play)™ plan to in several ways; for ...
(Date:7/29/2014)... In today’s world, a good night’s sleep has become especially ... (a medical problem where the airway collapses during sleep and ... rest they need to face their daily challenges. , ... people in the United States alone have sleep apnea. Of ... those treated, many cannot tolerate their prescribed medical device known ...
(Date:7/29/2014)... Dallas, Texas (PRWEB) July 29, 2014 Guests ... , will be indulged in a new sleep experience. The ... INTENTIONS™ Linens by Peacock Alley. , These expertly crafted, ... simple striped pattern from a distance, yet upon closer look, ... gentle reminders to relax, sleep and breathe. , ...
(Date:7/29/2014)... The Multiple System Atrophy Coalition, a growing nonprofit ... five new members to its Board of Directors. ... its executive directors. The MSA Coalition now has ... Advisors. These 12 dedicated volunteers are fully focused ... advocacy and research funding for the neurological disorder Multiple ...
Breaking Medicine News(10 mins):Health News:Four Seasons Resort Maui at Wailea Goes All Out to Give Couples Memorable Get-Away this Fall at Maui’s Luxury Resort 2Health News:Four Seasons Resort Maui at Wailea Goes All Out to Give Couples Memorable Get-Away this Fall at Maui’s Luxury Resort 3Health News:Outski launches 401(play)™ Plan to Employers as Part of an Employee Benefit / Health and Wellness Program 2Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Auberge Du Soleil Offers INTENTIONS™ by Peacock Alley on Guests' Beds Providing a Unique Sleep Experience 2Health News:The Multiple System Atrophy Coalition Appoints Five New Members to Board of Directors 2Health News:The Multiple System Atrophy Coalition Appoints Five New Members to Board of Directors 3Health News:The Multiple System Atrophy Coalition Appoints Five New Members to Board of Directors 4
... Wound Care,Innovations, LLC, a subsidiary of Wound ... the 510k clearance of a new wound,management product ... new addition to our product line (patent pending) ... (PSGAG) and will initially be available in gel ...
... Cord Blood,America, Inc. (OTC Bulletin Board: CBAI), the ... ) focused on,bringing the life saving potential of ... that a letter to shareholders from CEO Matthew,Schissler ... letter explains,some of the positive scientific and economic ...
... Corgenix Medical Corporation,(OTC Bulletin Board: CONX), a ... sales of $2,001,896 for the first fiscal,quarter ended ... quarter,ended September 30, 2007, a decrease of 4.9%. ... over the same period,in the prior fiscal year., ...
... China, Nov. 13 /Xinhua-PRNewswire-FirstCall/ -- China,Information Security ... Information,Security," "CIST" or the "Company"), a leading ... Information,Systems ("GIS") solutions provider to public security ... for 2009., China Information Technology has ...
... people choose to get representation when they apply for SSDI, a ... ... Belleville, IL (Vocus) November 13, 2008 -– Difficult decisions ... and one of the most important is how to begin the ...
... Nov. 13 TheraQuest Biosciences, Inc. a,development ... the U.S.,Food and Drug Administration (FDA) has ... TQ-1015, its abuse deterrent extended release,strong opioid. ... abuse deterrent technology., Najib Babul, PharmD, ...
Cached Medicine News:Health News:Wound Management Technologies, Inc. Announces FDA Clearance of 510k 2Health News:Wound Management Technologies, Inc. Announces FDA Clearance of 510k 3Health News:Cord Blood America Posts Letter to Shareholders: New Administration's Potential Enhanced Stem Cell Research Initiative Should Benefit the Company and Its Shareholders 2Health News:Cord Blood America Posts Letter to Shareholders: New Administration's Potential Enhanced Stem Cell Research Initiative Should Benefit the Company and Its Shareholders 3Health News:Corgenix Reports Financial Results for First Quarter of Fiscal 2009 2Health News:Corgenix Reports Financial Results for First Quarter of Fiscal 2009 3Health News:China Information Security Technology, Inc. Issues Guidance & Discuss Outlook for 2009 2Health News:China Information Security Technology, Inc. Issues Guidance & Discuss Outlook for 2009 3Health News:China Information Security Technology, Inc. Issues Guidance & Discuss Outlook for 2009 4Health News:China Information Security Technology, Inc. Issues Guidance & Discuss Outlook for 2009 5Health News:Getting Your Social Security Disability Benefits Can Be Easier With A Professional On Your Side 2Health News:Getting Your Social Security Disability Benefits Can Be Easier With A Professional On Your Side 3Health News:Getting Your Social Security Disability Benefits Can Be Easier With A Professional On Your Side 4Health News:Getting Your Social Security Disability Benefits Can Be Easier With A Professional On Your Side 5Health News:Getting Your Social Security Disability Benefits Can Be Easier With A Professional On Your Side 6Health News:TheraQuest's IND for Abuse Deterrent Strong Opioid (TQ-1015) Accepted by FDA 2
(Date:7/29/2014)... --   Glide Pharmaceutical Technologies ... an exclusive worldwide licence to an innovative prostate cancer ... University spin-out company.  Under the terms of ... development and commercial milestone payments, and royalties on future ... for additional exclusive licences to FScan diagnostic technologies, for ...
(Date:7/29/2014)... --   , First patient begins ... and safety of MSB0010718C in patients with metastatic Merkel cell ... skin cancer lacking effective treatments   MSB0010718C is also ... trial for the treatment of solid tumors that aims to ... subsidiary of Merck KGaA, Darmstadt, Germany , ...
(Date:7/28/2014)... -- Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC ) ... audio webcast to discuss financial results for the second quarter ... 31, 2014 at 4:30 p.m. ET. Conference ... 31, 2014 Time: 4:30 PM ET Listen via Internet: ... A webcast replay will be available on the Pharmacyclics ...
Breaking Medicine Technology:Glide Pharma Takes Exclusive Worldwide Rights to Novel Diagnostic Technology for Prostate Cancer 2Glide Pharma Takes Exclusive Worldwide Rights to Novel Diagnostic Technology for Prostate Cancer 3EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 2EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 3EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 4EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 5Pharmacyclics Announces Date of Conference call to discuss Financial Results for Second Quarter of 2014 2
... Prostate Conditions Education Council (PCEC) – a ... in prostate cancer screening – today announced it strongly ... Services Task Force (USPSTF). The draft guidance recommends against ... PCEC believes that until a more accurate and ...
... 10, 2011 PDI, Inc. (Nasdaq: ... R. Melillo, Jr. as senior vice president of Business ... drive PDI,s commercial outsource services and contract sales business. ... officer. Melillo was most recently general manager ...
Cached Medicine Technology:Prostate Conditions Education Council Opposes U.S. Preventative Services Task Force Recommendation 2Prostate Conditions Education Council Opposes U.S. Preventative Services Task Force Recommendation 3PDI Appoints Gerald R. Melillo, Jr. As SVP of Business Development 2
... rub formula is the most convenient multi-purpose ... in one bottle without the need to ... contact lenses and removes protein build-up when ... that contains Hydranate, a special ingredient that ...
Grafton Trial Frame...
The award-winning new Universal Trial Frame (UB4), the ergonomic refraction design from Oculus that's easier to use, easier to wear....
Half Eye Trial Frame - Adult...
Medicine Products: